… CAR-T therapy for relapsed refractory acute myeloid leukemia. … CAR-T therapy for relapsed
refractory acute myeloid leukemia. … -T therapy for relapsed refractory acute myeloid leukemia. …

… Kingdom who received InO before CAR T-cell therapy was compared with 27 children who
… given prior to CART-19 therapy, both on T-cell collection and outcome post CART-19, we …

… T-cell therapy is a new strategy for the treatment of relapsed and refractory acute lymphoblastic
… The short-term results were similar to those in our study; the overall complete remission …

… results from early phase trials in pediatric relapsed/refractory B ALL and CTL019 receipt
of the Food and Drug Administration Breakthrough Therapy status, CAR T cell therapy use is …

… However, the study does not investigate the survival profiles or factors influencing the
clinical outcomes by CAR-T therapy, leaving them still obscure in Chinese R/R B-ALL patients. …

… The anti-CD19 chimeric antigen receptor T-cell therapy … to treat relapsed or refractory pediatric
acute lymphoblastic leukemia… outcome is possible and produces similar economic results …

… Chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising treatment for
refractory haematological malignancies. Cytokine release syndrome and immune effector cell-…

… Strategies aimed at improving durability and long-term outcomes through improved CAR
T-cell persistence, multiantigen targeting, and optimization of patient selection will propel the …

… In this review, we highlight the pros and cons of targeting different antigens, including
clinical results published to date, as well as strategies to increase safety and efficacy of CAR-T …

… have published results on the use of different anti-CD19 chimeric antigen … chimeric
antigen receptor T-cell therapy for adult Philadelphia chromosome-positive acute lymphoblastic …